Peer Review History

Original SubmissionDecember 30, 2020
Decision Letter - Giancarlo Troncone, Editor

PONE-D-20-40536

A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma

PLOS ONE

Dear Dr. Huan Xin Zhang,,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 12 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Giancarlo Troncone

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. At this time, we ask that you please provide the full search strategy and search terms for at least one database used as Supplementary Information.

3. Thank you for including the statement that "The database search was conducted on XXXXXX". Please revise this statement to clarify whether all databases were searched from inception, or if there were any limits placed on the publication dates in your search.

4. Please ensure you have thoroughly discussed any potential limitations of this study within the Discussion section, including the potential impact of confounding factors.

5.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6.We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

7.PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The paper by Zhang entitled A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid

carcinoma covers an interesting subject. I suggest only minor text editing. In particular (line 37 page 2) the Authors affirms that "Less than 20% of surgically removed nodules are malignant". However, this statement it is correct only if it is referred to the FN/SFN Bethesda category. Indeed, I suggest to discuss in brief both the limit of FNA in particular in indeterminate categories and the use of miRNA in thyroid cytopathology specimens.

Reviewer #2: The manuscript entitled "A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma" highlighted that circulating microRNAs may be promising molecular markers for the diagnosis of 22 papillary thyroid carcinoma.

- The manuscript may benefit from a language revision by an English native speaker.

- The Authors should provide better quality figures.

- The Authors should address how selection bias have been solved.

- The Authors should better discuss if there are any difference in the role of serum and plasma extracted miRNAs in the diagnosis of PTC.

- The Authors should provide the extensive forms for all acronyms through the text when they first appear.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Point-to-point Reply to the comments

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found athttps://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdfhttps://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Reply: Thank you for your suggestions. In the revised manuscript, we modified the paper style include title, reference and so on to meet the PLOS One’s requirements.

2. At this time, we ask that you please provide the full search strategy and search terms for at least one database used as Supplementary Information.

Reply: Thank you for your careful comments. Full search strategy and search terms of this manuscript were sumarized in the supplement file 1.

3. Thank you for including the statement that "The database search was conducted on XXXXXX". Please revise this statement to clarify whether all databases were searched from inception, or if there were any limits placed on the publication dates in your search.

Reply: Thank you for your professional suggestions. We revised the statement and added the limits placed on the publication dates in page 4 line 71 to line 73 of the paper.

4. Please ensure you have thoroughly discussed any potential limitations of this study within the Discussion section, including the potential impact of confounding factors.

Reply: Thank you for your consideration suggestion. We have revised the discussion section according to your suggestion in page 11 line 228 to line 232 and page 12 line 241 to line 245 as well as page 13 line 268 to line 274 in the revised paper

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Reply: Thank you for your suggestions. This manuscrpt’s database were acquired from the published literatures, and the database were all showed in the article. Search strategy has been provided in the supporting data. At the same time, we deleted the Data Availability Statement at the end of the paper.

6. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Reply: We are so sorry for our negligence. In the revised version of the manuscript, we carefully re-check each Funding Information and revised them. But we can't change the information of fundings in the financial disclosure section. We have 5 fundings, which have been listed in detail at the end of the manuscript. However, only 4 fundings are displayed in the financial disclosure section, and we can't find a dialog box that can be modified. We would be greatly appreciated you for your consideration to help me update the information in financial disclosure section. We have request the updating of fundings in cover letter.

7. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

Reply: Thank you for your suggestions. I have registered ORCID ID number in your magazine, it is 0000-0002-9729-8995. I have updated my Information and authenticated the pre-existing iD in Editorial Manager, now, it has been validated in my Editorial Manager account.

8. Reviewer #1: The paper by Zhang entitled A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroidcarcinoma covers an interesting subject. I suggest only minor text editing. In particular (line 37 page 2) the Authors affirms that "Less than 20% of surgically removed nodules are malignant". However, this statement it is correct only if it is referred to the FN/SFN Bethesda category. Indeed, I suggest to discuss in brief both the limit of FNA in particular in indeterminate categories and the use of miRNA in thyroid cytopathology specimens.

Reply: Thank you for your insightful comments. According to your opinion, we discussed the the limit of FNA in indetermination particular categories and the use of miRNA in thyroid cytopathology specimens in page 11-12 from line 241 to line 245.

9. Reviewer #2: The manuscript entitled "A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma" highlighted that circulating microRNAs may be promising molecular markers for the diagnosis of papillary thyroid carcinoma.

9.1 The manuscript may benefit from a language revision by an English native speaker.

Reply: Thank you for your suggestions. The language of this manuscript was revised by an English native speaker. We hope that the revisions in the current manuscript will be sufficient for consideration of publication in ‘‘PLOS ONE

9.2 The Authors should provide better quality figures.

Reply: Thank you for your suggestions. In the revised version, we resubmit the new figures with higher resolution, we hope that it can meet the requirements of “PloS one”

9.3 The Authors should address how selection bias have been solved.

Reply: Thanks for your professional suggestion.9 literatures including 29 studies were analyzed in this study. The literatures were from Asian and European, and the heterogeneity test shows the I2 is very high (84%~90%). Higher heterogeneity which may be a selection bias, and may can influence the results, we used subgroup analysis to reduce the heterogeneity. The details are in the section of “subgroup analysis”.

9.4 The Authors should better discuss if there are any differences in the role of serum and plasma extracted miRNAs in the diagnosis of PTC.

Reply: Thanks for your thoughtful suggestion. We have revised the discussion section according to your suggestion in page 13 line 268 to line 274 in the revised paper

9.5 The Authors should provide the extensive forms for all acronyms through the text when they first appear.

Reply: Thank you for your careful comments. We have provided the extensive forms for all acronyms through the text when they first appear through the whole revised paper according to your suggestion.

Decision Letter - Giancarlo Troncone, Editor

A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma

PONE-D-20-40536R1

Dear Dr. Huan Xin Zhang

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Giancarlo Troncone

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I have no further comments to make. The Authors have addressed all the points raised by the reviewers.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Formally Accepted
Acceptance Letter - Giancarlo Troncone, Editor

PONE-D-20-40536R1

A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma

Dear Dr. Zhang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Giancarlo Troncone

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .